168 related articles for article (PubMed ID: 20483636)
1. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.
Goette NP; Lev PR; Heller PG; Kornblihtt LI; Korin L; Molinas FC; Marta RF
Cytokine; 2010 Jul; 51(1):67-72. PubMed ID: 20483636
[TBL] [Abstract][Full Text] [Related]
2. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
3. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
4. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia.
Goette NP; Lev PR; Heller PG; Glembotsky AC; Chazarreta CD; Salim JP; Molinas FC; Marta RF
Exp Hematol; 2010 Oct; 38(10):868-876.e1. PubMed ID: 20600579
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
6. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
11. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease.
Linnemann B; Kraft C; Roskos M; Zgouras D; Lindhoff-Last E
Thromb Res; 2012 Jun; 129(6):720-4. PubMed ID: 21982959
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
13. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
[TBL] [Abstract][Full Text] [Related]
15. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Kurosawa H; Okuya M; Matsushita T; Kubota T; Endoh K; Kuwashima S; Hagisawa S; Sato Y; Fukushima K; Sugita K; Okada Y; Park MJ; Hayashi Y; Arisaka O
J Pediatr Hematol Oncol; 2009 Sep; 31(9):678-80. PubMed ID: 19707158
[TBL] [Abstract][Full Text] [Related]
17. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
Aswad MH; Kissova J; Ovesna P; Říhová L; Penka M
Clin Hemorheol Microcirc; 2023; 84(4):359-368. PubMed ID: 37334581
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Tefferi A; Elliott M
Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
[TBL] [Abstract][Full Text] [Related]
20. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]